Nectar Lifesciences sell API and formulations business to Ceph Lifesciences for Rs. 1,270 Cr

Marksans to acquire Tevapharm's bulk formulations business

Plans to double its manufacturing footprint to bolster the growth

Panacea Biotec sells its domestic formulations business to Mankind Pharma

The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year

Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra

Domestic business was up 41.9% YoY and 27.7% QoQ

Wanbury FY26 PAT surges 117% to Rs. 66.1 crore

Ashish Mukkirwar appointed CFO of Jubilant Pharmova

The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives

Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore

Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore

Sun Pharma reports FY26 revenue of Rs. 58,220 crore, net profit at Rs. 11,479 crore

Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth

Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%

Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya